G. Ottaviani and N. Jaffe, The Epidemiology of Osteosarcoma, Cancer Treat Res, vol.152, pp.3-13, 2009.
DOI : 10.1007/978-1-4419-0284-9_1

C. Dass, E. Ek, K. Contreras, and P. Choong, A novel orthotopic murine model provides insights into cellular and molecular characteristics contributing to human osteosarcoma, Clinical & Experimental Metastasis, vol.8, issue.1, pp.367-80, 2006.
DOI : 10.1093/oxfordjournals.jbchem.a002824

K. Ando, M. Heymann, V. Stresing, K. Mori, F. Rédini et al., Current Therapeutic Strategies and Novel Approaches in Osteosarcoma, Cancers, vol.2012, issue.4, pp.591-616, 2013.
DOI : 10.1155/2012/523432

J. Anninga, H. Gelderblom, M. Fiocco, J. Kroep, A. Taminiau et al., Chemotherapeutic adjuvant treatment for osteosarcoma: Where do we stand?, European Journal of Cancer, vol.47, issue.16, pp.2431-2476, 1990.
DOI : 10.1016/j.ejca.2011.05.030

S. Patel, J. Lynch, T. Johnson, R. Carroll, C. Schumacher et al., Dose-Intense Ifosfamide/Doxorubicin/Cisplatin Based Chemotherapy for Osteosarcoma in Adults, American Journal of Clinical Oncology, vol.25, issue.5, pp.489-95, 2002.
DOI : 10.1097/00000421-200210000-00014

J. Clark, C. Dass, and P. Choong, A review of clinical and molecular prognostic factors in osteosarcoma, Journal of Cancer Research and Clinical Oncology, vol.25, issue.1, pp.281-97, 2008.
DOI : 10.3748/wjg.v10.i13.1984

K. Halvorson, M. Sevcik, J. Ghilardi, T. Rosol, and P. Mantyh, Similarities and Differences in Tumor Growth, Skeletal Remodeling and Pain in an Osteolytic and Osteoblastic Model of Bone Cancer, The Clinical Journal of Pain, vol.22, issue.7, pp.587-600, 2006.
DOI : 10.1097/01.ajp.0000210902.67849.e6

T. Guise, J. Yin, S. Taylor, Y. Kumagai, M. Dallas et al., Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis., Journal of Clinical Investigation, vol.98, issue.7, pp.1544-1553, 1996.
DOI : 10.1172/JCI118947

M. Grano, G. Mori, V. Minielli, F. Cantatore, S. Colucci et al., Breast Cancer Cell Line MDA-231 Stimulates Osteoclastogenesis and Bone Resorption in Human Osteoclasts, Biochemical and Biophysical Research Communications, vol.270, issue.3, pp.1097-100, 2000.
DOI : 10.1006/bbrc.2000.2569

E. Meulmeester, T. Dijke, and P. , The dynamic roles of TGF-?? in cancer, The Journal of Pathology, vol.403, issue.2, pp.205-223, 2011.
DOI : 10.1038/35000501

A. Lamora, J. Talbot, G. Bougras, J. Amiaud, M. Leduc et al., Overexpression of Smad7 Blocks Primary Tumor Growth and Lung Metastasis Development in Osteosarcoma, Clinical Cancer Research, vol.20, issue.19, pp.5097-112, 2014.
DOI : 10.1158/1078-0432.CCR-13-3191

M. Pines and A. Nagler, Halofuginone: A Novel Antifibrotic Therapy, General Pharmacology: The Vascular System, vol.30, issue.4, pp.445-50, 1998.
DOI : 10.1016/S0306-3623(97)00307-8

H. Koon, B. Fingleton, J. Lee, J. Geyer, E. Cesarman et al., Phase II AIDS Malignancy Consortium Trial of Topical Halofuginone in AIDS-Related Kaposi Sarcoma, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.56, issue.1, pp.64-72, 1999.
DOI : 10.1097/QAI.0b013e3181fc0141

M. Jin, S. Park, Y. Kim, G. Park, and S. Lee, Halofuginone induces the apoptosis of breast cancer cells and inhibits migration via downregulation of matrix metalloproteinase-9, International Journal of Oncology, vol.44, issue.1, pp.309-327, 2014.
DOI : 10.3892/ijo.2013.2157

P. Juárez, K. Mohammad, J. Yin, P. Fournier, R. Mckenna et al., Halofuginone Inhibits the Establishment and Progression of Melanoma Bone Metastases, Cancer Research, vol.72, issue.23, pp.6247-56, 2012.
DOI : 10.1158/0008-5472.CAN-12-1444

M. Leiba, J. Jakubikova, S. Klippel, C. Mitsiades, T. Hideshima et al., Halofuginone inhibits multiple myeloma growth in vitro and in vivo and enhances cytotoxicity of conventional and novel agents, British Journal of Haematology, vol.64, issue.6, pp.718-749, 2012.
DOI : 10.1124/mol.64.3.707

I. Spector, H. Honig, N. Kawada, A. Nagler, O. Genin et al., Inhibition of Pancreatic Stellate Cell Activation by Halofuginone Prevents Pancreatic Xenograft Tumor Development, Pancreas, vol.39, issue.7, pp.1008-1023, 2010.
DOI : 10.1097/MPA.0b013e3181da8aa3

J. Pinthus, Y. Sheffer, A. Nagler, E. Fridman, Y. Mor et al., INHIBITION OF WILMS TUMOR XENOGRAFT PROGRESSION BY HALOFUGINONE IS ACCOMPANIED BY ACTIVATION OF WT-1 GENE EXPRESSION, The Journal of Urology, vol.174, issue.4, pp.1527-1558, 2005.
DOI : 10.1097/01.ju.0000179218.16587.d2

A. Nagler, M. Ohana, O. Shibolet, M. Shapira, R. Alper et al., Suppression of hepatocellular carcinoma growth in mice by the alkaloid coccidiostat halofuginone, European Journal of Cancer, vol.40, issue.9, pp.1397-403, 1990.
DOI : 10.1016/j.ejca.2003.11.036

M. Elkin, H. Miao, A. Nagler, E. Aingorn, R. Reich et al., Halofuginone: a potent inhibitor of critical steps in angiogenesis progression, The FASEB Journal, vol.14, issue.15, pp.2477-85, 2000.
DOI : 10.1007/BF02631124

R. Abramovitch, H. Dafni, M. Neeman, A. Nagler, and M. Pines, Inhibition of Neovascularization and Tumor Growth, Facilitation of Wound Repair, by Halofuginone, an Inhibitor of Collagen Type I Synthesis, Neoplasia, vol.1, issue.4, pp.321-330, 1999.
DOI : 10.1038/sj.neo.7900043

Z. Gavish, J. Pinthus, V. Barak, J. Ramon, A. Nagler et al., Growth inhibition of prostate cancer xenografts by halofuginone, The Prostate, vol.51, issue.2, pp.73-83, 2002.
DOI : 10.1159/000058059

S. Xavier, E. Piek, M. Fujii, D. Javelaud, A. Mauviel et al., Amelioration of Radiation-induced Fibrosis, Journal of Biological Chemistry, vol.282, issue.15, pp.15167-76, 2004.
DOI : 10.1074/jbc.M300777200

D. Figueiredo-pontes, L. Assis, P. Santana-lemos, B. Jácomo, R. Lima et al., Halofuginone Has Anti-Proliferative Effects in Acute Promyelocytic Leukemia by Modulating the Transforming Growth Factor Beta Signaling Pathway, PLoS ONE, vol.6, issue.10, p.26713, 2011.
DOI : 10.1371/journal.pone.0026713.s001

A. Chou, D. Geller, and R. Gorlick, Therapy for Osteosarcoma, Pediatric Drugs, vol.25, issue.31, pp.315-342, 2008.
DOI : 10.1007/978-3-642-72643-9_3

C. Hattinger, M. Pasello, S. Ferrari, P. Picci, and M. Serra, Emerging drugs for high-grade osteosarcoma, Expert Opinion on Emerging Drugs, vol.24, issue.4, pp.615-649, 2010.
DOI : 10.1586/era.09.7

J. Van-oosterwijk, J. Anninga, H. Gelderblom, A. Cleton-jansen, and J. Bovée, Update on Targets and Novel Treatment Options for High-Grade Osteosarcoma and Chondrosarcoma, Hematology/Oncology Clinics of North America, vol.27, issue.5, pp.1021-1069, 2013.
DOI : 10.1016/j.hoc.2013.07.012

G. Grignani, E. Palmerini, P. Dileo, S. Asaftei, D. Ambrosio et al., A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study, Annals of Oncology, vol.65, issue.6, pp.508-524, 2012.
DOI : 10.1158/0008-5472.CAN-04-3135

S. Elmore, Apoptosis: A Review of Programmed Cell Death, Toxicologic Pathology, vol.135, issue.4, pp.495-516, 2007.
DOI : 10.1038/sj.embor.7400622

J. Chirgwin and T. Guise, Molecular Mechanisms of Tumor-Bone Interactions in Osteolytic Metastases, Critical Reviews?? in Eukaryotic Gene Expression, vol.10, issue.2, pp.159-78, 2000.
DOI : 10.1615/CritRevEukarGeneExpr.v10.i2.50

J. Chirgwin, K. Mohammad, and T. Guise, Tumor-bone cellular interactions in skeletal metastases, J Musculoskelet Neuronal Interact, vol.4, pp.308-326, 2004.

D. Javelaud, V. Delmas, M. Möller, P. Sextius, J. André et al., Stable overexpression of Smad7 in human melanoma cells inhibits their tumorigenicity in vitro and in vivo, Oncogene, vol.24, issue.51, pp.7624-7633, 2005.
DOI : 10.1074/jbc.M309798200
URL : https://hal.archives-ouvertes.fr/inserm-00147458

D. Javelaud, K. Mohammad, C. Mckenna, P. Fournier, F. Luciani et al., Stable Overexpression of Smad7 in Human Melanoma Cells Impairs Bone Metastasis, Cancer Research, vol.67, issue.5, pp.2317-2341, 2007.
DOI : 10.1158/0008-5472.CAN-06-3950
URL : https://hal.archives-ouvertes.fr/inserm-00147397

D. Padua, X. Zhang, Q. Wang, C. Nadal, W. Gerald et al., TGF?? Primes Breast Tumors for Lung Metastasis Seeding through Angiopoietin-like 4, Cell, vol.133, issue.1, pp.66-77, 2008.
DOI : 10.1016/j.cell.2008.01.046
URL : https://doi.org/10.1016/j.cell.2008.01.046

Z. Liang, T. Wu, H. Lou, X. Yu, R. Taichman et al., Inhibition of Breast Cancer Metastasis by Selective Synthetic Polypeptide against CXCR4, Cancer Research, vol.64, issue.12, pp.4302-4310, 2004.
DOI : 10.1158/0008-5472.CAN-03-3958

D. Heymann, B. Ory, F. Blanchard, M. Heymann, P. Coipeau et al., Enhanced tumor regression and tissue repair when zoledronic acid is combined with ifosfamide in rat osteosarcoma, Bone, vol.37, issue.1, pp.74-86, 2005.
DOI : 10.1016/j.bone.2005.02.020